Javier Morales, MD
Internal Medicine · Greenvale, NYNPI 1508806712
Payments from drug & device makers
Across 2,587 payments — averaging $520.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$466K
- Novo Nordisk$416K
- Bayer$135K
- Amgen$134K
- Eli Lilly$47K
- Novo Nordisk AS$45K
- plus $102K from 54 others
What the payments were for
- Consulting fees$255,25519%
- Speaking & faculty fees$878,82766%
- Travel & lodging$153,67011%
- Food & beverage$52,2084%
- Education$1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$177,901
- Ozempic$148,286
- JARDIANCE$136,441
- Repatha$129,750
- MOUNJARO$127,564
- Kerendia$119,374
- RYBELSUS$98,662
- Xultophy 100/3.6$63,558
- Victoza$38,155
- Tresiba$14,479
- VOQUEZNA$12,703
- Non-Covered$12,476
- FREESTYLE LIBRE 3$8,084
- TOUJEO$6,313
- Atellica IM 1300 Analyzer$5,674
- Yupelri$2,954
- Tryvio$2,835
- KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT$2,500
- Pogo Automatic Blood Glucose Monitoring System$2,479
- BAQSIMI$1,788
How this compares
$1,345,772 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 301 | $493,768 |
| MounjaroTirzepatide | 309 | $478,187 |
| JardianceEmpagliflozin | 278 | $371,547 |
| KerendiaFinerenone | 130 | $191,951 |
| TrulicityDulaglutide | 74 | $165,589 |
| EliquisApixaban | 96 | $117,683 |
| Repatha SureclickEvolocumab | 102 | $108,951 |
| FarxigaDapagliflozin Propanediol | 59 | $86,966 |
| XareltoRivaroxaban | 65 | $73,964 |
| EntrestoSacubitril/Valsartan | 55 | $52,843 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $49,215 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $41,318 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 13 | $30,464 |
| VascepaIcosapent Ethyl | 34 | $24,358 |
| RybelsusSemaglutide | 12 | $21,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $466,401 | $643,776383 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $415,799 | $534,072325 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $25,793 | $383,812292 claims |
| BayerKerendia | $135,270 | $191,951130 claims |
| PfizerEliquis, Premarin | $834 | $123,789110 claims |
| AstraZenecaFarxiga | $12,349 | $86,96659 claims |
| Johnson & JohnsonXarelto | $363 | $73,96465 claims |
| NovartisEntresto | $2,184 | $52,84355 claims |
| GSKTrelegy Ellipta | $275 | $41,31838 claims |
| AmgenEvenity (2 Syringes) | $133,785 | $30,46413 claims |
| Astellas Pharma US IncMyrbetriq | $442 | $19,29527 claims |
| AbbVieLinzess, Synthroid | $1,317 | $16,53476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Greenvale
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.